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The study of human cancers has provided evidence that malignant progression is associated with genetic change. It has been suggested that some
genetic alterations in tumors may be the result of direct or indirect processes related to environmental chemical exposure. This hypothesis has been
supported by genetic evidence in liver tumors which has associated aflatoxin B1 exposure with the detection of inactivating DNA mutations within
the human p53 tumor suppressor gene. The detection of activating ras oncogene mutations at high frequency in liver tumors of feral fish suggest
that the survey of mutations in genes, such as p53 or other genes, might provide a genetic signature for specific chemical exposure in tissues of
aquatic animals derived from environmentally damaged sites. - Environ Health Perspect 102(Suppl 12):75-80 (1994)
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Environmental Chemical
Exposure and Malignant
Progression
There is increasing evidence that human
cancers contain stable and heritable genetic
changes which may signify biologic mecha-
nisms to alleviate normal tissue growth
constraints (1). In addition, a substantial
body of knowledge indicates that specific
cellular proteins may be affected by such
changes at the DNA level. Such changes,
generally, can take the form of DNA (or
gene) loss, gene conversion (or transloca-
tion), mutation (inactivating or activating),
DNA amplification, or gene overexpres-
sion. Some DNA alterations have been
shown to result in modified function of
normal cellular gene products (2).
The progression of a normal cell to one
with malignant features requires the acqui-
sition of multiple and distinct genetic
changes resulting in modified growth fea-
tures that may be unique for specific tumor
forms derived from particular tissue-specific
progenitor cells. The rate at which such
changes occur may be contingent upon the
accumulation of rare genetic events that
enhance the replicative capacity of the
progenitor cell (3). Environmental chemi-
cals favoring the replicative capacity of the
progenitor (due to cytotoxicity) may
increase the likelihood of such rare and
heritable mutagenic events to occur (4). In
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addition, environmental chemicals that are
DNA damaging, may further enhance the
likelihood of achieving those genetic
changes since they may favor the reduction
ofgrowth restraints instrinsic to the cell or
imposed by neighboring cells in the tissue.
While the first such events may give only
a modest growth advantage and minor
changes in cytopathology, the probability of
that this cell will steadily accumulate genetic
changes increases as the proliferative capacity
ofthe cell is enhanced. In addition, DNA
repair processes may be overwhelmed or
reduced due to genetic alterations leading to
a further escalation of DNA damage. This
could result in a further alleviation ofnormal
growth controls. Some of these genetic
events may signify successful attempts ofthe
emergent malignant lesion to overcome tis-
sue-specific growth or immunologic con-
straints. In the case ofhuman cancer, this
process is best illustrated in human colorectal
cancerwhere genetic activation ofdominant-
acting oncogenes and loss oftumor suppress-
ing genes are features of the tumor. In
addition, accumulation ofthese alterations
marks sequential progression to more malig-
nant tumor forms (5).
The homeostasis ofnormal adult tissues
relies upon the ability oftissue-specific cell
progenitors to repopulate (mitosis), to give
rise to cell populations with defined func-
tion (differentiation), or to reduce the cell
number as part of tissue modeling and
regenerative processes (apoptosis) (Figure
1). Environmental chemicals perturb cellu-
lar homeostatic controls resulting in
increased mitosis and regenerative differen-
tiation following exposure to cytotoxic
agents. This is especially true of the liver,
in which many chemical substances are
processed for detoxification and in which
chronic liver damage and necrosis may
occur under conditions oflong-term expo-
sure. In addition, programmed cell death
or apoptosis may occur in those tissues
containing populations ofcells which enter
into the cell cycle in response to regenera-
tive process following cytotoxic injury. In
this case, cells may undergo active death
processes when cells are unable to divide or
differentiate.
Cancer Genetics and Cellular
Growth Control
The mechanistic connections relating alter-
ations ofspecific cellular oncoproteins and
tumor-suppressive proteins with the regula-
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Figure 1. Environmental chemicals and cell division.
Cells enter the cell cycle from a resting state (Go) and
are fated to divide (mitosis), differentiate, or die (apop-
tosis). Environmental chemicals may enhance the like-
lihood of mutation by stimulating cell division in
response as part of regenerative processes following
tissue injury. Genotoxic chemicals may modify the
DNA directly, leading to genetic alteration following
DNA synthesis (S) and mitosis. Cellular growth is regu-
lated by the number of cells entering the cell cycle (Go
to G1) and by cellular proteins which arrest cells
between G1 and S phases. Genetic alterations associ-
ated with cancer contain oncogene mutations and loss
of tumor suppressor gene function which may con-
tribute to a loss of cell growth control at the G1 to S
transition.
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tion of cellular growth control is just
emerging. Genetic alterations in cellular
protooncogenes may result in modified pro-
teins which impart transformation to nor-
mal cells. For example, transformation of
normal rat fibroblasts in tissue culture
involves at least two oncoproteins (6).
Studies such as these have classified onco-
gene products according to their relative
ability to transform normal cells. These
studies have indicated that multiple onco-
gene products are required to transform pri-
mary cultures ofnormal cells (for example,
ras and myc). In addition, transforming
viruses have been shown to be specific to
particular tissue types and encode specific
proteins which perturb normal growth con-
trol (for example, adenovirus Ela and Elb,
polyoma large T antigen, and human papil-
lomavirus E6 and E7 proteins). Moreover,
it has been shown that both viral oncopro-
teins and the loss of normal growth gene
function (tumor suppressor genes) may play
similar roles in the escalation ofthe cancer
process. In the case of tumor suppressor
genes, genetic alterations in the form muta-
tion or deletion have been shown to result
in the loss offunction ofthe gene (7).
Oncogenes and tumor suppressor genes
have been shown to encode proteins ofvar-
ied function in the cell. They have
included receptor tyrosine kinases (for
example, EGFR, PDGFR, HER-2, met, and
trk), nonreceptor tyrosine kinases (for
example, bcr-abl and src), serine-threonine
kinases (for example, raf1), GTP-binding
proteins and effectors (H-,K-, and N-ras,
G. , NF-I), transcription factors (for exam-
ple, c-, N-, and L-myc,fos,jun, bcl-3, WT-
1, p53), cell cycle regulators (for example,
p53, Rb, mdm2, and bc/-i), cell surface
proteins (for example, DCC, NF-2), and
death suppressors (for example, bcl-2)
(Figure 2). Much effort has been directed
towards cataloguing these alterations to
determine whether common genetic fea-
tures predominate in particular tumor
forms. In this regard, an extensive survey of
activating ras mutations (8) and loss-of-
function p53 mutations (9) has been con-
ducted using samples of human primary
tumors ofvaried tissue origin.
Chemical Exposure, Mutation,
and Carcinogenesis
As in the case ofhuman tumors, the sys-
tematic tabulation ofgenetic alterations in
rodent protooncogenes (ras) and tumor
suppressor genes (p53) has provided some
rationale to associate particular target genes
and specific genetic alterations with cancer
type and specific chemical etiology
(10-12). However, these have been con-
founded by findings which implicate differ-
ent target genes and genetic changes when
tumor samples ofdifferent animal models
yet similar pathology and chemical etiology
are compared.
For example, primary liver tumors have
been analyzed from rainbow trout, mice, and
rats induced with a single etiologic agent,
aflatoxin B1. Genetic analysis has revealed
that mice contain H-ras mutations in most
or all ofthe tumors examined (13). Trout
contain K-rasmutations in a majority ofthe
tumors (14) and rats contain K-ras or N-ras
mutations in a small subset ofliver tumors
(15,16). Using more sensitive detection
methods, K-ras mutations have been
detected in the majority ofsamples repre-
senting early and late-stage hepatocellular
adenomas and carcinomas obtained after
treatment ofrats with aflatoxin B, (17). In
contrast, other hepatocarcinogen-induced rat
liver tumors (18) and primary hepatocellular
carcinoma samples obtained from humans
contain few rasmutations even in those sam-
ples derived from individuals at geographic
riskfor mycotoxin exposure (19,20).
In humans liver tumors, the lack of ras
mutations was found to be in sharp contrast
to findings which have indicated that the
majority of human liver tumors contain
inactivatingp53mutations (9). This finding
is consistent with the the findings that asso-
ciate p53 mutations with the vast majority
of human tumors ofvaried tissue origin.
However, the frequent detection ofinacti-
vating p53 mutations in rodent tumors of
specific chemical etiology has been variable.
p53 Genetic alterations have been detected
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Figure 2. Genetic changes associated with human
cancer. Several DNA alterations have been shown to
be associated with human cancers resulting in pro-
teins localized to the membrane and nucleus of the
cell. The alterations have included single-base muta-
tions (p53, p21ras, NF-1, and Gip), increased transcrip-
tion (myc), DNA amplification (myc, mdm-2, EGMR,
PDGFR, and HER-2), translocation (bcr-abl, tpr-met,
bc/-1, bcl-2), and gene loss (p53, Rb, WT-1, NF-2,
DCC).
mouse skin tumors (21,22) and formalde-
hyde-induced rat squamous cell nasal carci-
nomas (23) whereas at low frequency in
rodent tumors ofliver (24-27), colon (28),
or lung (29) tissue origin.
In a general sense, these contrasting
observations may be due, in part, to the
complexities ofthe transformation process
itself. That is, while the ability of a given
chemical to induce DNA alterations (for
example, mutation or strand-break) may be
an important index of its potential cancer-
causing effect, many and different target
genes may be affected in a given tissue in a
given species by even a single etiologic
agent. This observation has been supported
by studies which have examined genetic
alterations associated with liver tumors of
human (HBV), woodchuck (WHV) , duck
(DHV), and ground squirrel (GSHV)
hepatitis virus etiology (30). In these cases,
c-myc or N-myc genes have been shown to
be amplified or activated by viral insertion
in liver tumors of GSHV or WHV etiol-
ogy, respectively, while such insertion
events have been absent in HBV-associated
human liver disease. These findings have
suggested that different mechanisms of
transformation may be operative in differ-
ent species in response to generalized
hepatic necroinflammatory disease. In
rodent tumors ofchemical etiology, it has
been shown that different strains of mice
exhibit differences in the type and fre-
quency of ras mutations which result in
response to exposure to the same chemical
agents. Some of these differences may be
explained, in part, on spontaneous
processes which may be operative in partic-
ular in-bred strain backgrounds (11).
Ecological Genetics and the
Cancer Process
The value ofecologic genetics relies upon
the founding principle that genetic alter-
ation in a given organism is enhanced by
exposure to harmful environmental agents.
It assumes that exposure to environmental
agents which do not lead to genetic change
are, by definition, less harmful. These prin-
ciples have been espoused for many years
by those who study the cancer process and
for which genetic change has been shown
to accompany the ability ofa tumor cell to
override those normal processes which
limit or regulate growth control. This has
been very clearly shown in strains ofinbred
rodents using tumor models where organ-
specific chemical exposure and tissue-
specific transformation events which occur
subsequent to exposure can be measured.
Moreover, there is a good correlation
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between those organ sites (such as the liver
or skin) that are physiologic sites for chem-
ical exposure or detoxification (in the case
of the liver and kidney) and those tissue
types which become malignant.
p53 Protein as a Short-term
and Long-term Sensor for
DNA Damage
Loss ofp53 and Rb (retinoblastoma tumor
suppressor protein) function may be the
two most common functional changes
which occur in human cancer. Unlike Rb,
p53 inactivation is most often accompanied
by gene mutation, overexpression of the
mutant p53 form, and loss of the normal
allele. In contrast, Rb function is lost by
gene deletion, occasional mutation leading
to low levels ofRb, or indirect mechanisms
to reduce normal Rb function. Moreover,
inactivating p53 mutations can occur at
many sites and mutation "hot spots" may
correlate to particular tumor cell types (9).
Studies have shown that normal p53 pro-
tein levels are elevated in response to DNA
damaging agents that arrest cells in the G1
phase of the cell cycle (31). This finding
supports many studies which have indicated
that activation ofoncogenes and inactiva-
tion of tumor suppressor genes (such as
p53) may lead to the alleviation ofgrowth
constraints which correlate with cyclin and
cyclin-dependent kinase activity in the cell
(Figure 3). In this regard, tumor mutations
in p53 have been shown to override DNA
damage-induced cell arrest. Moreover, p53
protein in combination with DNA damag-
ing chemicals may contribute to apoptotic
cell death (32).
All ofthese findings suggest that inacti-
vatingp53 mutations may serve to enhance
genetic instability by allowing chemicals to
induce mutations that would normally be
repaired prior to S phase. This model is
strengthened by the finding that p53 may
influence the function of the GADD45
DNA repair gene (33) or the
GIP1IWAF1ISDI1ICAP20 gene (34)
which have been found to be activated fol-
lowing exposure ofcells to DNA-damaging
agents. These and other findings are consis-
tent with a model where p53 may act to
suppress growth and may influence the reg-
ulation of processes of cellular stress or
mechanisms involving DNA replication
and repair (35). The role ofp53 in limit-
ing genetic instability is further strength-
ened by the finding that mice which are
null for the p53 gene are morphologically
normal but develop tumors at high fre-
quency in tissues of varied origin (36).
Recently, it was shown that the p53 null
mice supported a more rapid malignant
progression of chemically initiated skin
tumors with little effect on the number,
size and growth rate ofpremalignant papil-
lomas (37). All ofthese studies suggest that
p53 may function as a sensor of DNA
damage and inactivating mutations may
limit this function and lead to increased
proliferative capacity.
Aflatoxin B1 and Human Liver
Cancer: A Paradigm for p53
Gene Mutation and
Environmental Chemical
Exposure
There are few well-characterized genotoxic
chemicals which have a clear role in the
development of human disease.
Mycotoxins, ofwhich aflatoxin B1 is the
best studied, have been studied in rodents
and implicated in the etiology ofprimary
human hepatocellular carcinoma (38). The
correlations with human cancer have been
best illustrated using studies which have
shown that specific p53 mutations occur in
liver tumors ofhumans at risk for exposure
to aflatoxin B1. That is, hepatocellular car-
cinomas derived from individuals at rela-
tively low risk ofexposure to aflatoxin B1
possess few inactivating p53 mutations
(39-41). However, p53 inactivation by
mutation and gene loss was found to be
associated with the majority of human
hepatocellular carcinoma samples derived
from individuals residing in geographic
regions at risk for exposure to aflatoxins
(42,43). More important, a signature muta-
tion at codon 249 resulting in G to T base
transversions correlated with tumors of
individuals at risk to aflatoxin B1 exposure.
These findings were significant since a
wide variety ofsingle-base mutations have
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Figure 3. Cell growth control and cancer. The control of cell division is mediated by cyclins (A, B, D, and E) and
cyclin-dependent kinases (CDK). Receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (src-like TKs)
function as transducers of growth signals to the nucleus where effects on gene transcription lead to entry of cells
into the cell cycle. Activation of oncogenes (p21ras, MYC, raf-1, RTKs, bcl-1, bcl-2) and inactivation of tumor sup-
pressor genes (p53, Rb) allowfor progression into the cell cycle under growth conditions thatwould ordinarily limit
the growth of the cell.
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been shown to inactivate the p53 protein
and have been tabulated from human
tumors ofvaried tissue origins (9). The sig-
nature mutations at codon 249 were found
to be consistent with a substantial number
ofstudies in rodents and tissue culture sys-
tems that have studied mutations following
AFB1 exposure. These studies have deter-
mined aflatoxinBI DNA adduct forms that
occur exclusively with guanine residues and
preferred mutations resulting in G to T
base transversions (38). Recently, it has
been shown that aflatoxin Bi was found to
enhance the likelihood of mutation ofthe
p53 gene by a G to T base transversion at
codon 249 in cultured human HepG2 cells
(44). In contrast, mutations were not
detected in the region of codon 249 or
other exons within p53 genes derived from
rat liver tumors induced by exposure to
aflatoxin B, (25,26).
Genetic Epidemiology Using
Cancer Markers
Due to the substantial advances made in
human cancer genetics and analysis of ras
mutations in chemically-induced rodent
tumor models, several studies have been
performed as an attempt to correlate muta-
tion with genotoxic risk associated with
environmentally damaged sites. In these
cases, mutation leading to the activation of
oncogenes have been identified in tissues of
diseased aquatic animals (45). Specifically,
K-ras mutations have been detected in the
majority of diseased livers derived from
winter flounder associated with contami-
nated sediments ofBoston Harbor (46). In
addition, K-ras mutations have been
detected in the majority ofhepatic tumors
derived from Hudson River tomcod with
environmental risk to the development of
hepatocellular carcinoma (47). More
recently, transforming genes have been
detected in gonadal tumors derived from
bivalve mollusks (48).
In a broader sense, the basic principle
ofthese studies conforms to tenets applied
to genetic epidemiologic studies ofany sen-
tinel species including humans. This prin-
ciple suggests that specific genetic damage
as a result oflocal environmental chemical
hazards should be lacking when genetic
damage is assessed in individuals derived
from relatively "hazard-free" environments.
Ordinarily, cancer or its premalignant forms
are not features ofyoung or middle-aged
organisms in any healthy ecosystem. There-
fore, activating oncogene mutations or inac-
tivating tumor suppressor gene mutations
associated with precancerous abnormalities
in young or middle-aged individuals can
unequivocally be classified as harmful.
Moreover, those tissues which are exposed
to chemical contaminants (for example,
skin or liver) or which detoxify chemicals
(for example, liver or kidney) may repre-
sent primary organs of tissue and genetic
change.
p53 Protein as a Potential
Biomarkerfor Chemically
Induced DNA Damage
The level ofp53 protein in tissues ofani-
mals exposed to environmental chemicals
may be a good indicator of DNA damage
and cellular stress. This prediction follows
recent and increasing evidence to indicate
that p53 protein levels may become ele-
vated in response to genotoxic or other cel-
lular stresses associated with premalignancy
in human cancer (49-51). Measurement of
p53 protein levels in rodent models are few
(52). Analysis ofp53 protein levels follow-
ing DNA damage in rodent models is lack-
ing. Studies in rodents that would measure
levels ofp53 protein in varied target organs
following chemical exposure would provide
the basis for validating the use ofp53 levels
as ashort-term biomarkerofgenotoxic stress.
For the reasons outlined previously, the
primary DNA sequence ofthe p53 genetic
locus may provide a monitor of genetic
change in tissues exposed to potential
DNA damaging agents. The lack ofp53
mutations in tumors of inbred rodents
exposed to specific hepatocarcinogens has
suggested that the liver may not be the
best target organ for such analyses. In addi-
tion, p53 mutations have been detected in
high frequency in skin tumors resulting
from radiation exposure, suggesting that
skin lesions may provide a better source of
genetic material for analysis. Moreover,
there may be substantial differences in the
frequency of detection ofp53 mutations
between feral animals and inbred rodent
strains. This has already been illustrated in
the case ofactivating ras mutations where
a high frequency have been detected in
liver tumors of feral fish (46,47) com-
pared to the low frequency of ras muta-
tions detected in liver tumors ofrats exposed
to hepatocarcinogens (18).
To perform such studies, relevant p53
genes would need to be cloned and
sequenced. This would then be followed by
exon-specific PCR (polymerase chain reac-
tion DNA amplification) using using high-
fidelity polymerases as it has been done for
the human locus. The amplified DNA
would be subjected to analysis for muta-
tions using PCR-SSCP (single-strand con-
formation polymorphism) (53), PCR-mis-
match-cleavage analysis (54), primer-medi-
ated-RFLP (restriction fragment length
polymorphism) (55), or PCR-direct DNA
sequencing methods (46). Alternatively,
PCR DNA can be subjected to nested-
PCR to enable cloning into phage or alter-
native vectors followed by plaque screening
(16) or conventional DNA sequencing
methods. Once a limited database of
sequences has been obtained, more rapid
methods can be developed to survey for
particular single-base mutations. Some
complicating features of this analysis
include the presence ofnormal genes from
nonmalignant tissues in the sample, espe-
cially polyploid hepatocytes, which can
reduce the sensitivity ofmethods to detect
mutant p53 forms. In addition, p53 muta-
tions may occur late in the transformation
process, suggesting that early preneoplastic
lesions may not contain p53 mutations.
However, the ability to detect mutations
using PCR-based methods would be
enhanced by the feature ofcells containing
mutantp53 forms to eliminate normal p53
alleles.
Environmental Chemicals and
Genetic Toxicology: A Case
for Laboratory Studies
With regard to genetic epidemiology, the
conclusions that associate particular chemi-
cal biohazards to particular genetic muta-
tions will be, at best, correlative until
laboratory experiments are performed. The
testing ofsentinel species under controlled
environmental conditions would serve to
ascribe particular genetic changes resulting
from specific chemical exposure. This asso-
ciation may either be a direct consequence
(DNA adduct formation followed by
mutation) or indirect consequence ofDNA
damage (hepatotoxicity, regeneration, and
spontaneous mutation).
The complexities and diversity of
genetic changes which can overcome cellu-
lar growth control for a given cell type may
provide an overwhelming technical chal-
lenge as an attempt to localize ecosystem
damage or ascribe limits on allowed levels
ofspecific hazardous chemicals in a given
ecosystem. This limitation is, in part, driven
by the flexible capacity of normal cells to
achieve growth deregulation by selecting
varied species-specific subsets ofchemically
damaged genes which work to alleviate
growth constraint. Moreover, many genes
are modified at the level oftranscription (as
in the case ofp53 and c-myc) and would
not be measurable using DNA sample
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analysis. In this latter case, the potential
utility ofgeneric genotoxic markers (such as
elevated p53 protein levels) mayprove to be
more feasible since this may be a central fea-
ture ofDNA damage. Moreover, immuno-
histologic reagents may have reactivities
between aquatic species offish which would
enable their broad application.
In the long term, the identification of
signature mutations for specific classes of
environmentally damaging agents may have
some utility in ascribing impact ofspecific
biohazardous agents on the individual. The
analysis ofa few strategic surveys using sin-
gle genetic loci (p53 or K-ras, for instance)
in a few tissues (liver or skin) for a limited
number ofsentinel species (fish) would help
to provide the first steps in this area. The
surveys should comprise animals derived
from ecosystems where highly divergent yet
potentially hazardous agents (chemicals or
radiation) can be measured (water or sedi-
ment). This study would provide a founda-
tion for the genetic and epidemiologic prin-
ciples needed to ascribe ecotoxicologic risk
for particular classes of chemicals. The
analysis of such a study would validate
whether biomarker genes could be used as
indicators ofecosystem damage. In addi-
tion, this would provide a foundation for
further studies in the laboratory to associate
specific signature mutations with specific
and chronic chemical biohazard exposures.
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